Entrées par adminacticor

Acticor Biotech selects Catalent GPEx® Cell Line Development Technology to develop ACT-017

2 mars 2016 /dans , , /par

Acticor Biotech is developing an antibody fragment (Fab) considered as a first-in-class anti-thrombotic agent without bleeding risk in the primary treatment of ischemic strokes.   Paris, March 1st, 2016 – Acticor Biotech today announced that it selected Catalent’s proprietary GPEx® technology for the development of its Fab candidate, ACT-017, targeting the platelet glycoprotein VI (GPVI). […]